Redcare Pharmacy Shares: A Tale of Two Diverging Business Segments

Redcare Pharmacy's latest preliminary figures reveal a company caught in a powerful crosscurrent. While the digital prescription business is surging ahead, a notable slowdown in its core over-the-counter segment has triggered a sharp sell-off, sending its shares tumbling despite the broader market's positive performance.

Preliminary Figures Show Mixed Results

The German online pharmacy, listed on the MDAX, released preliminary numbers for the fourth quarter and full year 2025. At first glance, the growth appears robust. Group revenue for Q4 2025 climbed 18% year-over-year to reach €794 million. However, this result fell approximately 3% short of market consensus, a miss that has resonated strongly with investors.

The divergence between the company's business units is stark. Revenue from prescription medications (Rx) in Germany, fueled by the nationwide rollout of the digital prescription (E-Rezept), skyrocketed by 59% to €155 million in the fourth quarter, slightly exceeding expectations. In contrast, the non-prescription (Non-Rx) segment, which includes high-margin wellness and health products, grew by just 9%—a figure that also missed analyst estimates by 9%.

Key Performance Indicators at a Glance

The preliminary data for the full fiscal year 2025 and the final quarter paints a picture of strong overall growth, albeit with significant segmental imbalances:

• Full-Year 2025 Group Revenue: €2.9 billion (a 24% increase year-over-year)
• Q4 2025 Group Revenue: €794 million (+18% year-over-year, ~3% below consensus)
• Full-Year German Rx Revenue: €503 million (+98% year-over-year)
• Active Customer Base: 13.9 million (an addition of 1.4 million customers)
• Customer Satisfaction (NPS): 74 in Q4 (improved from 72 in Q3)

The expansion of the customer base and the stellar performance in Rx demonstrate the scalability of the model. Yet, the disappointment in the Non-Rx segment, a key profit driver, has tempered investor enthusiasm. The improved Net Promoter Score indicates operational progress in service delivery.

Market Reaction and Profitability Outlook

The immediate market response has been punitive. Redcare's stock emerged as one of the weakest performers on the MDAX, declining sharply in a single session. Trading around €67, the share price now sits more than 50% below its 52-week high, a stark contrast to the gains seen in the DAX and other leading indices.

Despite the revenue shortfall in Non-Rx, management has reaffirmed its full-year profitability guidance. The forecast for the adjusted EBITDA margin in 2025 remains unchanged at 2.0% to 2.5%, signaling confidence that the current growth deceleration will not derail near-term earnings.

Analyst Consensus Remains Elusive

The split in business performance is mirrored in a wide range of analyst assessments and price targets. Several institutions updated their views following the release:

• Jefferies maintains a "Buy" rating with a €150 price target. Analyst Martin Comtesse described a "mixed picture," acknowledging the high dynamism in Rx but noting significantly tempered growth in Non-Rx.
• Baader Bank also confirms its "Buy" recommendation, setting an even higher target of €175. Analyst Volker Bosse characterized the overall revenue development as solid but noted that high market expectations were not fully met.
• UBS adopts a more cautious stance, reiterating a "Neutral" rating with a fair value estimate of just €74. Analyst Olivier Calvet highlighted that Q4 revenues missed both his estimates and the consensus, primarily due to weaker demand for non-prescription products in international markets and the DACH region.

The extreme variance in targets—from €74 to €175—underscores the profound uncertainty regarding the company's medium-term trajectory.

The Path Forward

Operationally, Redcare is navigating a challenging landscape. It benefits from a powerful tailwind provided by the E-Rezept in Germany, yet faces a clear slowdown in its strategically vital Non-Rx arm, particularly outside its home market.

The next key milestone is scheduled for March 4, 2026, when the company will publish its audited annual results and full report. The market will then scrutinize detailed segment data, margin progression, and management's strategy for reinvigorating growth in the Non-Rx business. This will be crucial for determining whether the recent severe loss of investor confidence was an overreaction or a justified response to shifting fundamentals.

Ad

Redcare Pharmacy Stock: New Analysis - 07 January

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...

Ad

Redcare Pharmacy Stock: New Analysis - 07 January

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...